FDA clears Angle’s Parsortix breast cancer system

2022 07 28 17 23 1016 Breast Biopsy Mammotome 400

Angle has announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Parsortix PCI Clinical System for use with metastatic breast cancer (MBC) patients.

The FDA clearance is the first FDA product clearance to harvest cancer cells from a blood sample for subsequent analysis. This offers the prospect of a new era of personalized cancer care, according to the company.

The Parsortix system's ability to harvest cancer cells for analysis from a blood sample has the potential to transform treatment decisions for patients, as it allows for the opportunity for repeat noninvasive biopsies to assess cancer status. The Parsortix system's approach utilizes technology developed, owned, and patent-protected by Angle.

Page 1 of 5
Next Page